Stanley Erck, Novavax CEO (Lee Jin-wook/Yonhap via AP Images)

FDA re­view spot­lights risk of heart in­flam­ma­tion linked to No­vavax's Covid vac­cine — shares tum­ble

Shares of No­vavax $NVAX cratered af­ter the FDA’s brief­ing pa­pers hit Fri­day morn­ing spelling out con­cerns about po­ten­tial heart safe­ty is­sues with their long-await­ed Covid-19 vac­cine.

Ahead of the ex­pert pan­el re­view slat­ed for Tues­day, the agency re­view­ers ap­plaud­ed the vac­cine’s abil­i­ty to mean­ing­ful­ly re­duce the risk of mild to se­vere Covid-19. But they at­tract­ed much more at­ten­tion to a note on the FDA’s re­quest for No­vavax to change two kinds of heart in­flam­ma­tion — my­ocardi­tis and peri­cardi­tis — to an “im­por­tant iden­ti­fied risk.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.